

Research

Open Access

Amaranth oil application for coronary heart disease and hypertension

Danik M Martirosyan^{*1}, Lidia A Miroshnichenko², Svetlana N Kulakova³, Ala V Pogojeva³ and Vladimir I Zoloedov²

Address: ¹Functional Foods Center, Dallas, TX, USA, ²Voronezh State University, Voronezh, Russia and ³State Institute of Nutrition of the Russian Academy of Medical Sciences, Moscow, Russia

Email: Danik M Martirosyan* - ffc_usa@sbcglobal.net; Lidia A Miroshnichenko - LidaMir@mail.ru; Svetlana N Kulakova - LidaMir@mail.ru; Ala V Pogojeva - LidaMir@mail.ru; Vladimir I Zoloedov - LidaMir@mail.ru

* Corresponding author

Published: 05 January 2007

Received: 07 December 2006

Lipids in Health and Disease 2007, **6**:1 doi:10.1186/1476-511X-6-1

Accepted: 05 January 2007

This article is available from: <http://www.lipidworld.com/content/6/1/1>

© 2007 Martirosyan et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cardiovascular disease (CVD) is the Nation's leading killer for both men and women among all racial and ethnic groups. Development and progression of CVD is linked to the presence of risk factors such as hyperlipidemia, hypertension, obesity, and diabetes mellitus. It is known that cholesterol is an indicator of increased risk of heart attack and stroke. Low-density cholesterol (LDL) above 130 mg/dl high-density cholesterol (HDL) cholesterol below 35 mg/dl and total blood cholesterol above 200 mg/dl are indicators of problematic cholesterol. Proper ranges of cholesterol are important in the prevention of CVD.

It has been suggested that a reduction in the consumption of saturated and an increase in unsaturated fatty acids is beneficial and prevents CVD. Amaranth grain contains tocotrienols and squalene compounds, which are known to affect cholesterol biosynthesis. The cholesterol precursors squalene, lanosterol and other methyl sterols, reflect cholesterol synthesis [1-3], whereas plant sterols and cholestanol, a metabolite of cholesterol, reflect the efficiency of cholesterol absorption in normal and hyperlipidemic populations [4-6].

Qureshi with co-authors [7] showed that feeding of chickens with amaranth oil decreases blood cholesterol levels, which are supported by the work of others [8]. Previously, we have shown that Amaranth oil modulates the cell membrane fluidity [9] and stabilized membranes that could be one reason as to why it is beneficial to those who consume it. It is known that in hypertension, the cell membrane is defective and hence, the movement of the Na and K ions across the cell membranes could be defective that could contribute to the development of increase in blood pressure. Based on these properties of amaranth oil we hypothesize that it could be of significant benefit for patients with CVD.

Background

Amaranth is defined as a "never-fading flower" in Greek. Various *Amaranthus* species were grown by the Aztecs

5,000 to 6,000 years ago, prior to the disruption of the South American civilization by the Spanish conquistadors. Both the grain amaranth and leaves are utilized for

use for human as well as for animal food [10]. The nutritional value of amaranth has been extensively studied [11-14]. Grain amaranth has higher protein than other cereal grains and has significantly higher lysine content [15,16]. It has been shown that amaranth leaves are an excellent source of protein, with its maximal accumulation in the blossoming phase [17] (17.2–32.6% from dry weight for various samples).

Amaranth grain consists of 6 to 9% of oil which is higher than most other cereals. Amaranth oil contains approximately 77% unsaturated fatty acids and is high in linoleic acid, which is necessary for human nutrition. The lipid fraction is unique due to the high squalene content. Detailed studies on amaranth grain oil have been researched further in the last 2–3 decades [18-21]. Vegetable amaranth has received significantly less research attention than grain amaranth. However, it has been rated considerably higher in minerals, such as calcium, iron, phosphorous [22,23] and carotenoids [24] than most vegetables. Pharmacological properties of different amaranth species also have been investigated. It was determined that Amaranth paniculatus and Amaranth cruentus are good sources of flavanoids, especially for rutin, which are mostly produced in the stage of blossoming [25]. Usage of amaranth as livestock feed indicated relatively high protein qualities [26-28].

The vital issue with the future of amaranth can be determined by the end-use product. Since 1991, we are working on vegetable and grain amaranth commercialization by formulating and producing new amaranth products especially for the prevention and treatment of cardiovascular diseases such as coronary heart disease and hypertension. Our investigation indicated that amaranth grain is a good source of modern diet, particularly to make special products for the people who are at a high risk to cardiovascular diseases [29]. Furthermore, new formulas were created on the base of natural ingredients only with amaranth flour, containing a significant amount of magnesium and dietary fiber. This is extremely beneficial for people who have high blood pressure and are at a high risk of cardiovascular diseases such as heart attack [30].

Coronary heart disease is the most common cause of mortality. Risk factors for CVD include: hyperlipidemia, hypertension, obesity, and glucose intolerance. Several studies revealed that a reduction in blood pressure reduces the risk and incidence of CVD [31,32].

Studies clearly established that decreased consumption of saturated and trans fats is of significant benefit to those who have hypertension. In this context, it important to mention that consumption of products with low content of animal fat and increased use of unsaturated fats are of

benefit in hypertension and may reduce the risk of CVD. Amaranth oil can lower cholesterol in animal models in view of its rich content of squalene and polyunsaturated fatty acids. This is supported by the observation that hamsters which received hypercholesterolemic diets and were given Amaranth oil (5%), they experienced a decrease in total and non-high-density lipoprotein cholesterol by 15 and 22%, respectively, in comparison to the control group [33]. In the presented study, we investigated the effects of amaranth oil in patients suffering from coronary heart disease (CHD) and hypertension (HP) with obesity.

Methods and materials

The effect of amaranth oil was studied in a randomized placebo-controlled clinical trial of 125 patients with CVD. The patients were randomized to amaranth oil (3 ml amaranth oil provides a 100 mg squalene) 3–18 ml amaranth oil daily. All 125 patients got similar dietary and behavioral recommendations and low-salt diet. Biochemical and clinical indices was monitored during the treatment and after 3 weeks. The experiment was conducted on men and women, aged 32–68, suffering from coronary heart disease and hypertension accompanied by obesity. The following exclusion criteria were used:

1. Those having been affected with stroke, myocardial infarction, coronary angioplasty or having undergone an operation of aortocoronary shunting three months prior to the investigation.
2. Diagnosis of acute coronary deficiency three months prior to the investigation.
3. Renal insufficiency or liver failure.
4. The presence of acute or aggravated chronic diseases.

Eighty patients (85 people in the main group and 40 people in the group of comparison) suffering from coronary heart disease and hypertension in the 1st and 2nd stages accompanied by obesity of the 1st and 3rd stages were under observation.

All the patients received a reduced hyposodium antiatherogenic diet (HAD). The test group of patients received 3, 6, 12 and 18 ml. of amaranth oil instead of the sunflower oil. The control group received only the HAD.

Amaranth oil has been extracted from the *Amaranthus hybridus* L. (Amaranthaceae). Amaranth oil was applied in four doses by 3 ml. (100 mg squalene – 25% adequate level of consumption), 6 ml. (200 mg), 12 ml. (400 mg. – 100%) and 18 ml. (600 mg. – 150%) per day.

The overall duration of the clinical trial was 3 weeks. All the patients received a traditional course of treatment, which included the hyposodium antiatherogenic diet, exercise, and hydro and procedures. The test group and the control group were made of patients suffering from coronary heart disease and hypertension of the 1st and 2nd stages. A thorough medical examination was conducted. An electrocardiogram (ECG) and echocardiogram were conducted for the verification of the diagnosis. All patients in the test group were closely followed for any possible side effects due to the consumption of amaranth oil. Their organoleptic properties and tolerance were evaluated based on the availability and intensity of side effects as a result of the intake of the product. The clinical trials were conducted on the following groups of patients:

The patients of the comparison group – 40 people (2 male and 38 females) suffering from CHD and HP (average age was 52.4 years old). The patients of the first main group – 25 people (5 males and 20 females) suffering from CHD and HP (average age was 59.4 years old). They got a ration where 20 g sunflower oil have been replaced by amaranth oil and corn oil. The amount of squalene in this mix was

100 mg per a day. The patients of the second main group (200 mg squalene/day) – 20 patients (2 males and 18 females) suffering from CHD and HP (average age was 46.6 years old). The patients of the third main group (400 mg squalene/day) – 20 patients (3 males and 17 females) suffering from CHD and HP (average age was 59.2 years old). The patients of the fourth main group (600 mg squalene/day) – 20 patients (3 males and 17 females) suffering from CHD and HP (average age was 59.2 years old).

Description of Hyposodium Antiatherogenic Diet

The hyposodium antiatherogenic diet (HAD) is characterized by its low content of calories, small amounts of salt and fat, refined carbohydrates, cholesterol-containing products and extracted substances. The protein content in the ration corresponds to the physiological standard. It includes products containing lipotropic substances, polyunsaturated fatty acids, and food fibers. The description of the HAD diet is described below in Table 1.

Clinical methods of investigation

An integrated checkup of the patients in the Clinic included the study of signs for diseases such as: blood

Table 1: Chemical Composition of HAD and Rations including Amaranth Oil

Indices	HAD	Amaranth Oil (3 g/day)	Amaranth Oil (6 g/day)	Amaranth Oil (12 g/day)	Amaranth Oil (18 g/day)
Proteins, g	75	75	75	75	75
Fats, g	60	60	60	60	60
Carbohydrates, g	190	190	190	190	190
Caloricity, kcal	1600	1600	1600	1600	1600
Fatty acids:					
Unsaturated fatty acids	22.831	23.217	23.502	24.173	24.844
C 14:0	5.054	5.062	5.065	5.076	5.087
C 15:0	0.164	0.164	0.172	0.18	0.188
C 16:0	11.844	12.646	12.523	13.202	13.881
C 17:0	0.288	0.318	0.35	0.412	0.474
C 18:0	5.062	4.682	5.007	4.952	4.897
C 20:0	0.231	0.297	0.222	0.213	0.204
C 22:0	0.188	0.048	0.163	0.138	0.113
Monounsaturated fatty acids, g	21.423	22.515	21.285	21.147	21.009
C 14:1	0.455	0.455	0.455	0.455	0.455
C 16:1	1.852	1.879	1.86	1.868	1.876
C 17:1	0.008	0.008	0.008	0.008	0.008
C 18:1	18.707	19.708	18.515	18.323	18.131
C 20:1	0.207	0.241	0.253	0.299	0.345
C 22:1	0.194	0.224	0.194	0.194	0.194
Polyunsaturated fatty acids	15.129	13.724	14.32	13.511	12.702
C 18:2	13.424	11.761	12.560	11.696	10.832
C 18:3	0.275	0.533	0.330	0.385	0.440
C 18:4	0.015	0.015	0.015	0.015	0.015
C 20:4	0.355	0.355	0.355	0.355	0.355
C 20:5	0.042	0.042	0.042	0.042	0.042
C 22:5	0.902	0.902	0.902	0.902	0.902
C 22:6	0.116	0.116	0.116	0.116	0.116
PUFAs ω -6/PUFAs ω -3	10.2	7.533	9.192	8.254	7.384
Σ PUFAs ω -3	1.575	1.608	1.405	1.460	1.515

arterial pressure (BAP) level, heartbeat rate (HBR), EKG data, and the evaluation of organoleptic properties and tolerance to oil.

Biochemical methods of investigation

The biochemical indices were determined by means of the "SPECTRUM" analyzer (ABBOTT, USA). The content of low-density cholesterol in the blood serum, very low-density cholesterol (VLDL), and atherogenic coefficient value (AC) were evaluated in the rated manner.

$$\text{VLDL} = \text{TG}/2.2$$

$$\text{LDL} = \text{Total Cholesterol} - \text{TG}/2.2 - \text{HDL}$$

$$\text{AC} = (\text{Total Cholesterol} - \text{HDL})/\text{HDL}$$

The statistical treatment of the results was recorded in EXCEL, and was expressed as $M \pm m$. The significant level of the revealed differences was determined by using Student's t-criteria.

Results and discussion

The amaranth oil was extracted by press methods and the following physical and chemical characteristics were determined. The results are shown in Table 2.

It is known that amaranth grain contains 6 to 10% oil, which is mostly within the germ [34-36]. Amaranth oil is predominantly an unsaturated oil (76%) and is high in linoleic acid, which is necessary for human nutrition. Yanez E. with coauthors [37] showed that oil extracted from *Amaranthus cruentus* contained 19% palmitic acid, 3.4% stearic acid, 34% oleic acid and 33% linoleic acid. Docosaenoic acid (C22: 1) was present at the level of 9%. The ratio of saturated to unsaturated fatty acids was approximately 1:3. We provided an extraction of amaranth oil by press methods for the experiments. The fatty acid composition of amaranth oil was determined, which is provided in Table 3.

The investigation of He HP and others has shown that the major fatty acids in Amaranth oil consist of palmitic acid (19.1–23.4%), oleic acid (18.7–38.9%), and linoleic acid

(36.7–55.9%) [38]. The food and energy values of amaranth oil are shown in Table 4. As you can see, amaranth oil received by the press method has a great amount of squalene and tocopherols. It is known that squalene is an intermediate metabolite in the synthesis of cholesterol. Supplementation of squalene to mice has resulted in marked increases in cellular and non-specific immune functions in a dose-dependent manner [39]. Experimental evidence suggests that 90 percent of the newly formed squalene is stored in the lipid droplet and only 10 percent is used in cholesterol synthesis [40].

Evaluation of organoleptic properties and tolerance of amaranth oil

Based on a standard procedure, an extended testing of amaranth oil was made. The evaluation of its organoleptic properties and tolerance was conducted based on a fill-in-the-blank method. The organoleptic properties were evaluated based on 5 parameters of a five-score system. In addition, the tolerance of the oil was tested. The results received are presented in Tables 5 and 6 below.

As can be seen in Table 5, the overwhelming majority of patients (over 80%) highly enjoyed (put the highest score for) the oil quality. Much emphasis was made on its beneficial organoleptic properties. Pleasant outward appearances, homogeneous consistence and the absence of foreign inclusions were also established. The properties of the amaranth oil met the required standards. A growing number of the patients placed a lot of emphasis on its amiable taste.

The percents indicate the number of people polled. None of the participants taking part in the testing mentioned an unpleasant "aftertaste". As can be seen in Table 6, the tolerance of amaranth oil was good. Throughout the clinical trials, no single case of intolerance, dyspepsia occurrences, allergic reactions or other side effects were established. Upon the completion of the clinical trials, all of the patients expressed their willingness to continue the intake of the certified amaranth oil under house conditions.

It has been reported that a combination of fish oil supplementation and salt restriction is highly effective in lower-

Table 2: Physico-Chemical Characteristics Of Amaranth Oil

Physico-Chemical Characteristics	Characteristics of Amaranth Oil
Iodine number, mg	130
Acid number, mg KOH/g,	2.9
Mass fraction of the non fat admixtures in %	0.2
Mass fraction of the phosphor containing substances in P ₂ O ₅ %	0.1
Mass fraction of moisture and volatile substances, %	0.1
Peroxide number, mmole/kg of active oxygen	2.4

Table 3: Fatty Acid Composition of Amaranth Oil

Fatty acids (Shorthand designation)	Mass Fraction of Fatty Acids (in %)	
	Press methods	Chemical extraction
14:0	0.14	0.15
15:0	0.15	0.08
16:0	19.19	18.59
16:1	0.13	0.08
17:0	1.05	1.37
18:0	3.38	4.45
18:1	22.64	22.69
18:2	49.89	48.00
18:3 ω 6	0.35	0.35
18:3 ω 3	1.01	0.92
20:0	0.16	0.27
20:1	1.04	1.49
22:0	0.32	0.24
24:0	0.05	0.08
22:1	0.07	0.7
24:1	0.43	0.54

ing systolic and diastolic blood pressure [41]. After four weeks the mean systolic blood pressure had decreased by 8.9 mm Hg and the diastolic pressure by 6.0 mm Hg.

The researchers concluded that sodium restriction combined with fish oil supplementation lowered blood pressure in elderly people with normal blood pressure. It has been shown that supplementation with 7.7 to 9 grams/day of fish oil will reduce systolic blood pressure by 4 mm Hg and diastolic pressure by 3 mm Hg in hypertensive individuals [42]. Table 7 shows how the systolic blood pressure decreased with the amaranth oil treatment combined with the HAD.

The weight loss for the control group and the group of patients with an amaranth diet did not have a big difference. The weight loss was about 5.1–6.5%, which is related to the HAD.

Table 4: Food and Energy Value of 100 g Amaranth Oil

Food value	Amaranth Oil
Triglycerides (g)	78
Squalene (g)	5.9
Phospholipids (g)	8
Phytosterols (g)	2
Sum of tocopherols (vitamin E), in mg	300
Carotinoids (mg)	0.5
Energy value, kcal/kj	711/87

Table 5: Value Of Amaranth Oil's Organoleptic Properties

Indices	Number of Scores	Amaranth Oil
Outward Appearance	5	100%
	4	0
Odor	5	83%
	4	17%
Color	5	98%
	4	0
Taste	5	92%
	4	8%
Consistence	5	100%
	4	0

Evaluation of the dynamics of the clinical indices during diet therapy with the inclusion of amaranth oil

The diet therapy with amaranth oil contributed to the decrease or disappearance of headaches, weakness, increased fatigability, shortness of breath during a physical activity, edema of legs toward the evening hours and feeling of intermission of heart function in most patients.

The positive dynamics on electrocardiograms were observed in 40–50% of patients and were displayed by rhythm normalization (disappearance of sinus tachycardia, bradycardia, single ventricular and supraventricular extrasystole), decrease in the intensity of the signs of coronary deficiency (which was evident by the change in the interval S-T and wave T).

Results given in Table 7 shows that the level of systolic arterial pressure was decreased by 18%, 19%, and 21% in the course of the treatment in patients of the 1st, 2nd and 3rd of the main group and the groups of comparison – by 18%, diastolic – by 14%, 15%, 19% and by 17%. In addition, heart rate in the course of the treatment tended to decrease in patients of all the groups.

The degree of decrease in excess body weight in the course of the treatment of the patients in the main groups and the groups of comparison amounted to 6.5%, 6.2%, 5.1% and 6.1%. The average daily loss of body weight for the patients of the main groups and the groups of comparison was equal to 304 g, 348 g, 219 g and 271 g, accordingly.

Evaluation of the dynamics of biochemical indices during diet therapy with the inclusion of amaranth oil

It is known that there is a correlation between diet and cholesterol level in blood serum. Alpha-linolenic acid (ALA), omega-3 fatty acid, found in large amounts in flaxseed oil is not effective in lowering triglyceride levels, a risk factor for heart disease [43]. A group of researchers conducted a study in people with a history of heart disease, using the Mediterranean diet [44]. The Mediterranean diet included a special margarine high in alpha-

Table 6: Evaluation Of Tolerance Of Amaranth Oil

Indices	Amaranth Oil 3 g (100 mg squalene per day)	Amaranth Oil 6 g (200 mg squalene per day)	Amaranth Oil 12 g (400 mg squalene per day)	Amaranth Oil 18 g (600 mg squalene per day)
Eructation	0	0	0	0
Nausea	0	0	0	0
Heartburn	0	0	0	0
Bitter taste in mouth	0	0	0	0
Pains in the abdomen	0	0	0	0
Allergic reactions	0	0	0	0

linolenic acid. Those people assigned to the Mediterranean diet had a 70% reduced risk of dying from cardiovascular diseases compared with the control group during the 27 months. Similar results were reported by others as well [45]. Nevertheless, the success of the Mediterranean diet does not prove that ALA protects against heart disease [46]. The influence of an antisclerotic diet with a sour-milk product enriched with an extract of leaves of an amaranth in patients with ischemic heart disease and hypertension was investigated by Zoblkova ZS and coauthors [47]. As a result of the diet with extracts of amaranth leaves were positive dynamic of clinic manifestation and lipid spectrum of blood.

It is evident from Table 8 that inclusion of amaranth oil in the HAD contributed to a statistically significant decrease in the total cholesterol level in the blood serum in patients of the 1st, 2nd and 3rd of the main groups and the groups of comparison, accordingly, by 14%, 17%, 20% and 12% and triglycerides and VLDL Cholesterol – by 13%, 21%, 36% and 16%, LDL – by 19%, 23%, 25% and 12%, the value of atherogenic ratio – by 18%, 23%, 32% and 8%. The contents in the blood serum HDL in patients of the 3rd main group had a tendency towards increase, in the main groups it virtually remained unchanged, and in the group of comparison it decreased by 9%. The level of the remaining investigated biochemical indices changed

to the same degree in the patients of the main groups and the group of comparison. It is known, that low HDL cholesterol and high LDL cholesterol are more specifically linked to cardiovascular disease than is total cholesterol [48].

The link between high triglyceride levels and cardiovascular diseases is not as well established as the link between high cholesterol and heart disease. But, according to some studies, a high triglyceride level is an independent risk factor for cardiovascular diseases in some people [49].

It is known that squalene is involved in cholesterol synthesis, but it is not clear yet squalene's role in the process of lowering the cholesterol amount in blood serum. Even more, dietary supplementation with one gram of squalene daily for nine weeks was reported to cause increases in VLDL and LDL-cholesterol concentrations by 34 and 12 percent, respectively. However, a subsequent six-week period on a lower dose of squalene dietary supplementation (0.5 g/day) normalized serum sterols [50].

Evaluation of fatty-acid composition of cell membrane in patients with coronary heart disease and hypertension

Studies have shown that replacing saturated fat with unsaturated fat in the diet can help lower blood pressure. For example, Fish oils containing eicosapentaenoic acid

Table 7: Dynamics of Clinical Characteristics under the Effects of Diet and Amaranth Oil

Clinical Attributes	HAD	Amaranth Oil 3 g (100 mg squalene per day)	Amaranth Oil 6 g (200 mg squalene per day)	Amaranth Oil 12 g (400 mg squalene per day)	Amaranth Oil 18 g (600 mg squalene per day)
Systolic Blood Pressure (mm Hg)	1	146 ± 2.13	143 ± 7.58	142 ± 2.48	149 ± 2.42
	2	121 ± 2.08**	118 ± 2.28**	116 ± 2.92**	120.6 ± 1.40**
Diastolic Blood Pressure (mm Hg)*	1	96.8 ± 2.59	87.5 ± 3.61	98.1 ± 1.01	97.5 ± 2.13
	2	82 ± 1.8*	76.7 ± 1.36*	85.2 ± 1.86**	80.9 ± 0.8**
Frequency of Heart Contraction (hit/min)	1	82.2 ± 2.50	76.2 ± 2.8	78.2 ± 2.23	78.8 ± 2.13
	2	69.3 ± 2.92	68 ± 2.7	67.4 ± 2.94	68.0 ± 2.17
Weight (kg)	1	93.4 ± 2.51	85.9 ± 4.138	97.9 ± 3.98	117.9 ± 4.66
	2	87.7 ± 1.98	81.2 ± 3.28	91.5 ± 3.82	110.6 ± 3.40

1 – Before Treatment, 2 – After Treatment

Table 8: Dynamics of biochemical characteristics of patients under the effects of diet and amaranth oil

Biochemical Sings		HAD	Amaranth Oil 3 g (100 mg squalene per day)	Amaranth Oil 6 g (200 mg squalene per day)	Amaranth Oil 12 g (400 mg squalene per day)	Amaranth Oil 18 g (600 mg squalene per day)
Total cholesterol mmol/L	1	6.31 ± 0.23	7.06 ± 0.6	5.58 ± 0.23	5.76 ± 0.23	6.60 ± 0.23
	2	5.57 ± 0.20*	5.69 ± 0.3*	4.79 ± 0.20*	4.76 ± 0.20*	5.29 ± 0.20*
Triglycerides mmol/L	1	1.34 ± 0.13	1.57 ± 0.2	1.88 ± 0.13	1.17 ± 0.13	2.49 ± 0.13
	2	1.13 ± 0.10	1.45 ± 0.18	1.62 ± 0.10	0.93 ± 0.10	1.58 ± 0.10
HDL Cholesterol mmol/L	1	1.65 ± 0.11	1.66 ± 0.32	1.16 ± 0.11	1.26 ± 0.11	1.15 ± 0.11
	2	1.51 ± 0.07	1.42 ± 0.22	1.13 ± 0.07	1.24 ± 0.07	1.19 ± 0.07
LDL Cholesterol mmol/L	1	4.03 ± 0.20	4.69 ± 0.44	3.90 ± 0.20	3.74 ± 0.20	4.42 ± 0.20
	2	3.54 ± 0.17	3.61 ± 0.26	3.18 ± 0.17	2.89 ± 0.17	3.32 ± 0.17
VLDL Cholesterol mmol/L	1	0.61 ± 0.06	0.71 ± 0.09	0.99 ± 0.06	0.58 ± 0.06	1.25 ± 0.06
	2	0.51 ± 0.04	0.66 ± 0.08	0.81 ± 0.04	0.46 ± 0.04	0.79 ± 0.04
Aterogenic Index (AI)	1	3.15 ± 0.27	3.65 ± 0.41	4.06 ± 0.27	3.80 ± 0.27	5.21 ± 0.27
	2	2.90 ± 0.25	3.47 ± 0.44	3.33 ± 0.25	2.98 ± 0.25	3.54 ± 0.25

1 – Before Treatment, 2 – After Treatment

AI = (Total Cholesterol - HDL): HDL under $p < 0.05$; ** under $p < 0.01$.

(EPA) and docosahexaenoic acid (DHA) have been found more effective in lowering triglyceride levels and blood pressure [51].

The analysis of the fatty acid composition of erythrocyte membrane of patients was conducted based on a traditional method of gas-liquid chromatography. The investigation results are presented in Table 9 below.

The treatment based on a basic diet along with the inclusion of amaranth oil brought about a dose-dependant action in respect to oleic acid (18:1), the content of which increased to the maximum (by 16%) when using a 6 ml of amaranth per day. The concentration of linoleic (18:2) and linolenic acids (18:3) decreased in the course of diet therapy in patients of all the groups. Along with this, a dose-dependant action in respect to a long chain polyunsaturated fatty acid of omega family 3 – docosapentaenoic (22:5) and docosahexaenoate (22:6) was established. If the concentration of these acids in erythrocyte membranes decreased in patients suffering from coronary heart disease and hypertension who received a diet with a content of 6 ml of amaranth oil per day, then the concentration of erythrocyte membranes increased by 9% and 18% in patients of the 2nd main group and by 9% and 28% in patients of the 3rd main group.

The total increase in membranes polyunsaturated fatty acids was evident only in patients of the 3rd main group. Simultaneously, in the course of diet therapy a maximal decrease of part unsaturated fatty acids in erythrocyte membranes.

Hence, changes in the fatty-acid composition of erythrocyte membranes under the influence of various doses of amaranth oil are evident and were only expressive when

using 18 ml of oil on a daily basis. Apparently, the observed clinical effects were related not only to the change in fatty-acid composition of diet, but also the squalene content in it.

Estimation of the antioxidant action of amaranth oil in patients with CVD

Antioxidants are important components of nutrition which prevent the formation of free radicals, inhibit them or participate in their destruction process, help to avoid oxidative stress, and provide protection from chronic diseases [52].

Amaranth grain and its oil fraction have antioxidative effect on streptozotocin-induced diabetic rats.⁵³ The authors suggest that amaranth grain and amaranth oil supplements, as an antioxidant therapy, may be beneficial for correcting hyperglycemia. However, there are not enough investigations about amaranth oil antioxidant properties specifically for humans. Below are the results of our study about amaranth oil antioxidant properties for humans.

As can be seen in Table 10, the enrichment of food ration by amaranth oil had an essential positive effect on the peroxide oxidation of lipids – antioxidant protection (POL - AP), manifesting by reduction in the products of the peroxide oxidation of lipids (diene conjugates and the malonic dialdehyde of plasma) and by growth of the ferments of antioxidant protection (glutathione reductase (GR), glutathionperoxidase(GP), superoxidisedismutase (SODM), catalase(CAT).

Thus, in particular, the diet therapy resulted in the reduction in the diene conjugates of plasma (DC) and of malonic dialdehyde (MDA) in the basic groups of patients

Table 9: The effect of amaranth oil on fatty-acid composition of erythrocyte membrane of patients

Fatty Acids		HAD	Amaranth Oil 3 g (100 mg squalene per day)	Amaranth Oil 6 g (200 mg squalene per day)	Amaranth Oil 12 g (400 mg squalene per day)	Amaranth Oil 18 g (600 mg squalene per day)
12:0	1	--	0.35	1.14	1.22	1.07
	2	--	0.34	0.57	1.26	0.90
14:0	1	2.02	5.2	2.18	2.23	2.19
	2	1.44	4.11	0.97	2.89	1.99
15:0	1	2.9	2.28	0.61	0.62	0.77
	2	2.08	2.29	0.44	0.76	0.72
16:0	1	15.9	24.99	15.4	18.44	19.6
	2	17.75	16.1	23.0	16.40	17.8
16:1	1	3.98	4.68	0.88	1.09	1.30
	2	2.87	6.04	0.82	2.91	1.44
17:0:1	1	3.28	5.04	1.11	1.27	1.41
	2	2.55	2.87	1.07	1.27	1.41
18:0	1	12.81	8.22	11.70	12.45	12.24
	2	11.55	11.29	14.78	11.15	12.15
18:1	1	14.29	20.4	14.05	14.95	14.85
	2	14.93	17.76	15.43	15.09	17.17
18:2	1	8.48	9.65	11.05	11.61	11.57
	2	9.96	10.78	12.67	11.13	10.74
18:3	1	1.7	0.57	0.40	0.69	0.52
	2	0.88	0.8	0.11	0.19	0.26
20:0	1	--	0.22	0.57	0.45	0.63
	2	--	0.2	0.33	0.49	0.34
20:1	1	--	0.66	0.84	0.79	0.96
	2	--	1.07	0.61	0.95	0.81
20:2	1	--		0.63	0.51	0.43
	2	--		0.35	0.55	0.56
20:3	1	1.64	1.66	2.53	1.96	2.17
	2	1.16	1.31	1.50	1.57	2.22
20:4	1	15.03	5.77	15.33	13.66	11.7
	2	14.95	10.93	14.04	14.75	14.15
20:5	1	1.45	2.05	4.06	4.64	3.80
	2	1.03	4.23	1.08	3.00	2.40
22:1	1	--	0.83	2.75	2.80	3.82
	2	--	1.5	1.89	3.00	3.14
22:4	1	5.4	1.71	0.52	0.53	0.54
	2	5.65	1.27	0.83	0.50	0.46
24:0	1	3.55	0.18	0.23	0.19	0.18
	2	4.51	0.22	0.18	0.22	0.22
22:5	1	2.6	1.0	2.91	2.13	2.05
	2	2.32	1.31	1.77	2.30	2.22
22:6	1	5.42	2.46	9.40	6.99	6.45
	2	6.41	4.1	7.10	8.26	8.05
24:1	1	--	0.73	1.10	0.84	0.94
	2	--	0.63	0.94	1.00	1.02
Sum of omega 3	1	11.17	6.08	16.77	14.31	12.88
	2	10.64	10.44	10.23	13.75	12.37
Sum of PUFAs	1	50.2	25.82	46.83	42.59	39.43
	2	42.36	35.5	38.94	42.26	40.56
Sum of UFAs	1	37.18	47.03	31.83	35.6	36.68
	2	37.33	34.55	40.27	33.17	34.12

1 – Before Treatment, 2 – After Treatment

PUFAs – Polyunsaturated fatty acids

UFAs – Unsaturated fatty acids

Table 10: Dynamics of the indices of POL – AP system in Patients with Ischemic Heart Diseases and Hyperlipidemia (M ± m)

Indices	HAD	Amaranth Oil				
		3 g (100 mg squalene per day)	6 g (200 mg squalene per day)	12 g (400 mg squalene per day)	18 g (600 mg squalene per day)	
DC, nmole/ml	1	4.12 ± 0.34	4.98 ± 0.39	5.71 ± 0.77	5.35 ± 1.05	5.49 ± 0.49
	2	3.75 ± 0.29	4.13 ± 0.27	4.06 ± 0.42	5.07 ± 0.71	5.45 ± 0.81
MDA, nmole/ml	1	3.02 ± 0.17	4.4 ± 0.28	2.37 ± 0.34	2.688 ± 0.39	2.5 ± 0.49
	2	2.66 ± 0.08	3.38 ± 0.19	1.27 ± 0.12	2.118 ± 0.36	2.49 ± 0.49
GP, micromole/min/ml	1	20.6 ± 0.62	22.3 ± 3.77	23.4 ± 3.43	26.2 ± 1.61	24.1 ± 4.16
	2	20.4 ± 0.51	22.6 ± 3.61	23.88 ± 4.45	28.5 ± 0.99	22.4 ± 0.78
GR, micromole/min/ml	1	1.81 ± 0.14	1.77 ± 0.1	1.158 ± 0.42	0.57 ± 0.1	1.31 ± 0.18
	2	1.97 ± 0.09	1.98 ± 0.27	1.7 ± 0.98	0.8 ± 0.34	1.58 ± 0.74
SODM nominal units/ml	1	2816 ± 160	1826 ± 42.4	2112 ± 83.96	1991 ± 34.63	1998 ± 43.1
	2	3098 ± 148	1810 ± 26.3	2365 ± 77.12	2267,8 ± 70.0	2338 ± 100
CAT, kU/ml	1	183 ± 11.3	203 ± 33.3	223 ± 23.53	226 ± 17.23	178 ± 37.88
	2	226 ± 9.93	225 ± 25.8	281.8 ± 20.87	208.8 ± 4.2	244 ± 30.66

1 – Before Treatment, 2 – After Treatment

Diene Conjugates (DC), Malonic Dialdehyde (MDA), Peroxide Oxidation of Lipids – Antioxidant Protection (POL -AP), Glutathione Reductase (GR), Superoxidedismutase (SODM), catalase (CAT).

respectively to 17–29% and 21–46%, accordingly. In the patients of the comparison group, the reduction in the data of indices composed 9% and 12%.

It is noted also the considerable growth of the ferments of antioxidant protection proportional to the concentration of amaranth oil in the diet. In this case, the greatest dynamics are fixed in a change in the levels of glutathione reductase (GR) and of catalase (CAT) in basic groups to 12%, 47%, 42%, 21% and 11%, 26%, 8%, 37%, and in the patients of the group of comparison to 10% and 23%, accordingly.

The estimation of the immunomodulating action of amaranth oil in patients with ischemic heart diseases and hyperlipidemia

Humoral immunity has been suggested to play an important role in the diseases for both adults and children, but

the function of neutralizing antibody responses in delaying disease progression has not been fully established [54–58].

The results of investigating the indices of humoral immunity are given in Table 11.

According to the immunogram, the levels of IgM and IgG content in the blood serum of patients before treatment and after treatment was within the norm (0,5–2,0 g/l for IgM; 5,3–16,5 g/l for IgG).

It is known that Il-1 β appears cytokin of the wide spectrum of action, produced predominantly by macrophages. It causes the starting reactions of immunity and plays a key role in the development of inflammation. Il-1 β also plays one of the central roles in the inflammatory reac-

Table 11: Dynamics of the Indices of Humoral Immunity in Patients with Ischemic Heart Diseases and hyperlipidemia under the effect of the basic therapy with the application amaranth oil (M ± m)

Indices	HAD	Amaranth Oil				
		3 g (100 mg squalene per day)	6 g (200 mg squalene per day)	12 g (400 mg squalene per day)	18 g (600 mg squalene per day)	
IgM, mg/ml	1	0.79 ± 0.07	0.81 ± 0.07	2.25 ± 0.96	1.82 ± 0.78	1.0 ± 0.33
	2	0.73 ± 0.03	0.87 ± 0.06	2.43 ± 1.04	1.98 ± 0.78	1.2 ± 0.21
IgG, mg/ml	1	4.32 ± 0.37	4.33 ± 0.97	8.25 ± 0.45	5.56 ± 1.86	11.28 ± 1.76
	2	4.45 ± 0.7	5.63 ± 0.1	10.23 ± 3.89	7.33 ± 2.66	15.27 ± 0.13
IL-4, pg/ml	1	13.7 ± 2.8	8.91 ± 1.9	15.0 ± 3.3	7.67 ± 2.19	12.75 ± 4.66
	2	15.64 ± 2.2	11.0 ± 3.2	17.78 ± 5.79	12 ± 3.22	16.5 ± 2.51
IL-1 β , pg/ml	1	173.9 ± 20.97	186.4 ± 25.3	8.0 ± 1.41	4.0 ± 1.22	4.32 ± 1.16
	2	150.7 ± 19.52	112.6 ± 21.32	4.62 ± 1.53	2.84 ± 1.02	2.38 ± 0.06

1 – Before Treatment, 2 – After Treatment

tion, in response to the bacterial infection and the tissue damages.

Raising the level of Il-1 β is observed with different inflammatory and autoimmune diseases, including cardiovascular pathology. Statistically reliable reduction of its content in the blood serum in patients, who had an amaranth oil intake, contained respectively 100, 200, 400 and 600 mg of squalene (to 39%, 42%, 28% and 45%) and an improvement in the clinical state of patients. Furthermore, patients who had a standard diet intake had a 14% reduction.

The level of free fraction Il-4 in the blood serum of patients who consumed amaranth oil exceeded initially to 26%. After the course of treatment, there was an increase in the content of cytokin in the blood serum of patients who consumed amaranth oil, contained 100, 200, 400 and 600 mg of squalene, accordingly to 24%, 19%, 57% and 29% ($r < 0,05$). Furthermore, patients who had a standard diet intake had a 14% reduction. As primary targets, Il-4 serves B-lymphocytes for which it is the strongest growth factor. In other words, there was an improvement in the humoral immunity of patients. It was then established that amaranth oil possesses high biological activity.

This is true because amaranth oil contains 77% of polyunsaturated fatty acids, from which 50% comprises the linoleic acid. Furthermore, amaranth oil is characterized by the high content of such biologically active compounds, such as: squalene (up to 8%), tocopherols (to 2%), phospholipids (to 10%), and phytosterols (to 2%). A good germicidal action is established, and also the high regeneration and antitumorogenic properties of amaranth oil. Amaranth oil increases the antioxidant and immunomodulating property of HAD.

In conclusion, the results of the present study shows that amaranth oil can reduce the amount of cholesterol in blood serum, and it can be recommended as a functional food product for the prevention and treatment of cardiovascular diseases. Diet with amaranth oil may help reduce blood pressure and could serve as an effective alternative to drug therapy in people with hypertension. This investigation also showed that a combination of amaranth oil with a hyposodium antiatherogenic diet is more effective to reduce the amount of blood cholesterol than just the hyposodium antiatherogenic diet. The next step of our investigation is to study mechanism of cholesterol lowering properties of amaranth oil. Squalene as well as phytosterols can be involved in that mechanism. As you can see on the Table 4 amaranth oil contains great amount of phytosterols, which are chemical homologs of cholesterol. Phytosterols interfere with the micellar solubiliza-

tion of cholesterol in the intestine and reduce the efficiency of cholesterol absorption [59].

Conclusion

1. The inclusion of amaranth oil in the diet has a beneficial action upon the clinical presentation of Coronary Heart Disease and Hypertension. Its beneficial action is seen best when used at a dose of 18 ml per day.

2. Amaranth oil decreases the amount of total cholesterol, triglycerides, LDL and VLDL significantly. The concentration-dependent cholesterol lowering effect of characterizing amaranth oil has been proven.

3. The inclusion of amaranth oil in the diet contributes to an increase in the concentration of polyunsaturated fatty acids, particularly, long-chain acid of omega 3 families in patients suffering from hypertension and coronary heart disease.

4. Our studies indicate that Amaranth oil can be considered as an effective natural antioxidant supplement capable of protecting cellular membranes against oxidative damage.

Abbreviations

Hyposodium Antiatherogenic Diet (HAD), Atherogenic Coefficient value (AC), Diene Conjugates (DC), Malonic Dialdehyde (MDA), Peroxide Oxidation of Lipids – Antioxidant Protection (POL -AP), Glutathione Reductase (GR), Superoxidedismutase(SODM), Catalase(CAT), Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), PUFAs – Polyunsaturated Fatty Acids, UFAs – Unsaturated Fatty Acids

References

- Miettinen TA: **Detection of changes in human cholesterol metabolism.** *Ann Clin Res* 1970, **2**:300-320.
- Miettinen TA: **Serum squalene and methyl sterols as indicators of cholesterol synthesis in vivo.** *Life Sci* 1969, **8**:713-721.
- Kempen HJM, Glatz JFC, Gevers Leuven JA, van der Voort HA, Katan MB: **Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.** *J Lipid Res* 1988, **29**:1149-1155.
- Miettinen TA, Tilvis RS, Kesäniemi YA: **Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.** *Am J Epidemiol* 1990, **131**:20-31.
- Tilvis RS, Miettinen TA: **Serum plant sterols and their relation to cholesterol absorption.** *Am J Clin Nutr* 1986, **43**:92-97.
- Miettinen TA, Tilvis RS, Kesäniemi YA: **Serum cholesterol and plant sterol levels in relation to cholesterol metabolism in middle-aged men.** *Metabolism* 1989, **38**:136-140.
- Qureshi AA, Lehmann JW, Peterson DM: **Amaranth and its oil inhibit cholesterol biosynthesis in 6-week-old female chickens.** *J Nutr* 1996, **126**(8):1972-8.
- Berger A, Gremaud G, Baumgartner M, Rein D, Monnard I, Kratky E, Geiger W, Burri J, Dionisi F, Allan M, Lambelet P: **Cholesterol-lowering properties of amaranth grain and oil in hamsters.** *Int J Vitam Nutr Res* 2003, **73**:39-47.
- Martirosyan Danik M, Mnatsakanian Vilen A, Gulxandarian Armen A: *Algunas Caracteristicas Bioquimicas y Biofisicas Del Aceite Extraido De sem-*

- illas De Cuatro Epecies De Amarantos (*Amaranthus* spp.), *Journal "Amarantos"*, agosto, Argentina, ISSN 0327-3989 1994:1-3.
10. Tucker JB: **Amaranth: the once and future crop.** *Bioscience* 1986, **36**:9-13. 59-60
 11. Becker R, Wheeler EL, Lorenz K, Stafford AE, Grosjean OK, Betschart AA, Saunders RM: **A composition study of amaranth grain.** *J Food Sci* 1981, **46**:1175-1180.
 12. Teutonico RA, Knorr D: **Amaranth: Composition, properties, and applications of a rediscovered food crop.** *Food Technol* 1985, **39**:49-60.
 13. Martirosyan DM: **Amaranth as a Nutritional Supplement for the Modern Diet.** *Amaranth Legacy, USA* 2001, **14**:2-4.
 14. Martirosyan DM: **Amaranth, Quinoa and Lentils as a Source of Modern Diet and Functional Foods.** In *Book: Non-Traditional Natural Resources, Innovation Technologies and Products* Moscow, Russia, Russian Academy of Natural Sciences; 2003:91-100.
 15. Bressani R: **The proteins of grain amaranth.** *Food Rev Int* 1989, **5**:13-38.
 16. Lehman J: **Proteins of grain amaranth.** *Legacy* **2**:3-6 *Amer. Amaranth Inst* 1989.
 17. Kadoshnikov Sergey I, Kadoshnikova Irina G, Martirosyan Danik M: **Investigation of Fractional Composition of the Protein in Amaranth.** In *Book "Non-Traditional Natural Resources, Innovation Technologies and Products"* Issue 12 Moscow, Russian Academy of Natural Sciences, Moscow; 2005:81-104.
 18. Lyon CK, Becker R: **Extraction and refining of oil from amaranth seed.** *J Am Oil Chem Soc* 1987, **64**:233-236.
 19. Yorge Soriano Santos: **Chemical Characteristics of Amaranth oil.** *Ciencia* 1992, **45**:113-119.
 20. Martirosyan Danik M, Mnatsakanyan Vilen A, Gyluchandaryan Armen A: **Biochemical and Biophysical characteristics of the four species of Amaranth.** *Journal Amaranthos, Argentina* . 1994, August, 1-3
 21. Pogojeva AV, Gonor KV, Kulakova SN, Miroshnichenko LA, Martirosyan DM: **Effect of Amaranth Oil on Lipid Profile of Patients with Cardiovascular Diseases.** In *Book Functional Foods for Chronic Diseases* Edited by: Martirosyan DM. Dallas, USA; 2006:35-45.
 22. Makus DJ, Davis DR: **A mid-summer crop for fresh greens or canning – vegetable amaranth.** *Ark Farm Res* 1984.
 23. Igbokwe PE, Tiwari SC, Collins JB, Tartt JB, Russell LC: **Amaranth – A potential crop for southwestern Mississippi.** *Res. Report 13 No. 10.* *Mississippi Agr & Forestry Expt Sta, Mississippi State Univ, Mississippi State* 1988.
 24. Martirosyan DM, Kadoshnikov SI, Bil' KY, Tchernov IA, Kulikov YA: **Carotenoids Accumulation in the Amaranth and its Role in Cancer Prevention.** *Book: Phytotherapy with Biological Active Substrates on the Basis of Natural Sources, Chernogolovka, Russia* 2004:100-112.
 25. Martirosyan DM, Kadoshnikov SI, Borsukov PA, Kadoshnikova IG, Agababyan EY, Kamalyan NS, Mnatsakanyan VA: **Pharmacological Properties of Amaranth.** *Legacy*. 2003, **15**:6-10.
 26. Sanchez JMC: **Amaranth (*Amaranthus* spp.) as forage.** *Proc. Fourth Amaranth Conf, Minnesota Ext. Serv, Minnesota Agr, Univ Minnesota, St Paul* 1990.
 27. Kadoshnikov SI, Martirosyan DM, Kadoshnikova IG, Tchernov IA: **A study on the Silage Use of Plain and Combined Amaranth in Ontogenesis.** *Legacy* 2001, **16**(1):4-8.
 28. Sleugha Byron B, Mooreb Kenneth J, Brummerb E Charles, Knappb Allan D, Russellb James, Gibsonb Lance: **Forage Nutritive Value of Various Amaranth Species at Different Harvest Dates.** *Crop Science* 2001, **41**:466-472.
 29. Martirosyan DM, Sekoyan ES, Kadoshnikov SI, Kadoshnikova IG, Sargsyan AV, Parsadanyan RA, Taskov KV: **Amaranth as a Source of Functional Foods.** In *The 2004 International Conference Proceeding* Edited by: Martirosyan DM, Yensen NP. Dallas, USA:68-73. November 16-17, 2005
 30. Martirosyan DM, Sargsyan AV, Parsadanyan RA: **Functional Food for the Prevention of Hypertension.** In *Book Functional Foods for Cardiovascular Diseases* Edited by: Martirosyan DM. Dallas, USA; 2005:200-205.
 31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: **Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT).** *JAMA* 2002, **288**:2981-2997.
 32. Hata , Yoshiya : **A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects.** *American Journal of Clinical Nutrition* 1996, **64**:767-71.
 33. He HP, Cai Y, Sun M, Corke H: **Extraction and purification of squalene from amaranthus grain.** *J Agric Food Chem* **50**(2):368-72. 2002 Jan 16
 34. Whelton , Paul K: **Effects of oral potassium on blood pressure.** *Journal of the American Medical Association* **277**:1624-32. 1997 May 28
 35. Betschart AA, Irving DVW, Shepherd AD, Saunders RM: **Amaranthus cruentus: milling characteristics, distribution of nutrients within seed components, and the effects of temperature on nutritional quality.** *J Food Sci* 1981, **46**:1181-1187.
 36. Lorenz K, Hwang YS: **Lipids in amaranths.** *Nutrition Reports International* 1985, **31**:83-89.
 37. Yanez E, Zacarias I, Granger D, Vasquez M, Estevez AM: **Chemical and nutritional characterization of amaranthus (*Amaranthus cruentus*).** *Arch Latinoam Nutr* 1994, **44**(1):57-62.
 38. Czerwinski J, Bartnikowska E, Leontowicz H, Lange E, Leontowicz M, Katrich E, Trakhtenberg S, Gorinstein S: **Oat (*Avena sativa* L.) and amaranth (*Amaranthus hypochondriacus*) meals positively affect plasma lipid profile in rats fed cholesterol-containing diets.** *J Nutr Biochem* 2004, **15**(10):622-9.
 39. Gregory S, Kelly ND: **Squalene and Its Potential Clinical Uses.** *Altern Med Rev* 1999, **4**(1):29-36.
 40. Tilvis R, Kovanen PT, Miettinen TA: **Metabolism of squalene in human fat cells. Demonstration of a two-pool system.** *J Biol Chem* 1982, **257**:10300-10305.
 41. Cobiac , Lynne : **Effects of dietary sodium restriction and fish oil supplements on blood pressure in the elderly.** *Clinical and Experimental Pharmacology and Physiology* 1991, **18**:265-68.
 42. Morris , Clare Martha: **Does fish oil lower blood pressure? A meta-analysis of controlled trials.** *Circulation* 1993, **88**(2):523-33.
 43. Layne KS, Goh YK, Jumpsen JA: **Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels.** *J Nutr* 1996, **126**:2130-40.
 44. De Lorgeril M, Salen P, Martin J-L: **Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diety Heart Study.** *Circulation* 1999, **99**:779-85.
 45. De Lorgeril M, Salen P, Martin J-L: **Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diety Heart Study.** *Circulation* 1999, **99**:779-85.
 46. Rice RD: **Mediterranean diet.** *Lancet* 1994, **344**:893-4.
 47. Zoblkova ZS, Shcherbakova SA, Pogozheva AV, Dmitrievskaia MN, Gonor KV, Mal'tsev Glu: **The effect of diet with the sour-milk product enriched with amaranth on parameters of antioxidant protection at patients with a cardiovascular pathology.** *Vopr Pitan* 2004, **73**(5):21-3.
 48. Kwiterovich PO Jr: **The antiatherogenic role of high-density lipoprotein cholesterol.** *Am J Cardiol* 1998, **82**:Q13-21.
 49. Gotto AM Jr: **Triglyceride as a risk factor for coronary artery disease.** *Am J Cardiol* 1998, **82**:Q22-5.
 50. Miettinen TA, Vanhanen H: **Serum concentration and metabolism of cholesterol during rapeseed oil and squalene feeding.** *Am J Clin Nutr* 1994, **59**:356-363.
 51. Ferrara , Aldo L: **Olive oil and reduced need for antihypertensive medications.** *Archives of Internal Medicine* **160**:837-42. March 27, 2000
 52. Briedis V, Povilaitytė V, Kazlauskas S, Venskutonis PR: **Polyphenols and anthocyanins in fruits, grapes wines, and avaluation of their antioxidant activity.** *Medicina* 2003, **39**(2):104-111.
 53. Kim Hye Kyung, Kim Mi Jeong, Cho Hong Yon, Kim Eun-Ki, Shin Dong Hoon: **Antioxidative and anti-diabetic effects of amaranth (*Amaranthus esculantus*) in streptozotocin-induced diabetic rats.** *Cell Biochem Funct* 2006, **24**(3):1.
 54. Hogan CM, Hammer SM: **Host determinants in HIV infection and disease. Part I: cellular and humoral immune responses.** *Ann Intern Med* 2001, **134**:761-776.
 55. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC: **Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.** *J Infect Dis* 1997, **176**:924-932.

56. Ross HA, Rodrigo AG: **Immune-mediated positive selection drives human immunodeficiency virus type I molecular variation and predicts disease duration.** *J Virol* 2002, **76**:11715-11720.
57. Geffin R, Hutto C, Andrew C, Scott GB: **A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type I.** *Virology* 2003, **310**:207-215.
58. Hutto C, Zhou Y, He J, Geffin R, Hill M, Scott W, Wood C: **Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type I infection in perinatally infected twins with discordant disease courses.** *J Virol* 1996, **70**:3589-3598.
59. Ostlund RE Jr, Lin X: **Regulation of cholesterol absorption by phytosterols.** *Curr Atheroscler Rep* 2006, **8(6)**:487-91.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

